Drug Profile
Research programme: protein therapeutics - Arana Therapeutics/GlaxoSmithKline
Latest Information Update: 19 Apr 2011
Price :
$50
*
At a glance
- Originator EvoGenix; GlaxoSmithKline
- Developer Arana Therapeutics
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 10 Aug 2009 Arana Therapeutics has been acquired by Cephalon
- 27 Nov 2008 EvoGenix has successfully completed the second project for GlaxoSmithKline
- 28 Mar 2007 EvoGenix has successfully completed the first project for GlaxoSmithKline